Price
No data yet.
Social Signal Score
Analyst Ratings
1 analystRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Indranil Dey
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 6
- Beta
- 0.91
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -6.59
Financials
Revenue
$0.00-100.0%Net Income
$-2.32MEBITDA
$-2.32MFree Cash Flow
$-1.64MEPS (diluted)
$-1.12Shares Outstanding (diluted)
2.08M+10470.7%Operating Expenses
$2.35MCash & Debt
$9.60MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-6.85M | $-15.25 |
| 2024 | $0.00 | $-7.72M | $-456.76 |
| 2023 | $0.00 | $-9.95M | $-290.48 |
| 2022 | $249.0K | $-9.30M | $-292.88 |
| 2021 | $0.00 | $-3.73M | $-118.68 |
| 2020 | $0.00 | $-1.13M | $-56.76 |
| 2019 | $0.00 | $-757.7K | $-38.20 |
Valuation
BJDXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80+0.00%Social Signal Score
Mentions (3)
- Newsaccessnewswire.com·5h ago·Negative
… Milestone as Bluejay Advances the Symphony™ IL-6 Test Toward Regulatory Submission ACTON, MA / ACCESS Newswire / October 6, 2026 / Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company focused on improving patient outcomes through its Symphony™ near-patient diagnostic platform, today announced baseline clinical characteristics from the SYMON-II clinical validation study, highlighting a substantial and diverse population of critically ill patients an…
View source ↗ - Newsglobenewswire.com·28d ago·Positive
Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets Partnership Establishes Federal Distribution and Co-Marketing Framework Across VA, DoD, Military Health Systems and Other Government Healthcare Channels Partnership Establishes Federal Distribution and Co-Marketing Framework Across VA, DoD, Military Health Systems and Other Government Healthcare Channels
View source ↗ - Newsglobenewswire.com·54d ago·Negative
…s Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization ACTON, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on improving patient outcomes in critical care settings, today reported financial results for the quarter ended June 30, 2026 and provided an update on the Company's clinical, regulatory and manufacturing progress.
View source ↗
Earnings
Fri, Nov 13(in 5 weeks)
Consensus estimate $-3520.00 per share
Typical surprise +97.5% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-1.12 vs $-3520.00beat
- Thu, Aug 7$-5.64 vs $-144.00beat
- Tue, May 13$-13.48 vs $-1152.00beat
- Mon, Mar 31$-449.48 vs $-832.00beat
Estimates and results for BJDX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BJDX officers and directors.
- Bought
- $406k
- Sold
- $49k
18 trades
1 trade
- Hrt Financial Lpsold
- Hrt Financial Lpbought
- Wurth Douglas Clarkbought
- Dey Indranilbought
- Chase Donald Rbought
- Zeidman Fred Sbought
- Dey Svetlanabought
- Dey Svetlanabought
61 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in BJDX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.